CREATIVITY in BIOTECH

How to organise serendipity?

29 June @10 am CEST

Approaches to treat disease are becoming increasingly complex and creative, with the biotech industry recently demonstrating its key role in the development of new drug modalities and technologies. To keep up with this relentless pace, companies rely more and more on external innovation and benefit greatly if they manage to also leverage innovation from within their organisation.

But how can companies 'organise' creativity and innovation? Is there a science behind developing new ideas? How to provide freedom to be creative, while supporting urgency and purpose at the same time?

We will dig into this topic with innovation experts and innovation makers in the field of biopharmaceutical and biotechnology.

AGENDA

10:00	"*The knowledge innovation matrix: In search of research and impact opportunities*" - **Lykke Margot Ricard**, University of Southern Denmark "From uncertainty to innovation: A matter of mindset and process" - **Kirstin Kohler**, Professor for user experience design and design innovation at the University of Applied Sciences Mannheim *"BioMed X Institute – Seeding biomedical innovations"* - **Thomas Rückle**, BioMed X Institute in Heidelberg
11:00	Active break, sponsored by "Die Techniker - TK"
11:20	CELIS Challenges
12:00	Speed Networking
13:00	Wrap-up

REGISTRATION

CELIS is funded by the European Union's COSME Programme (GA No.: 873857)

SPEAKERS

Lykke Margot Ricard is Associate Professor of Innovation Management and Technology at the University of Southern Denmark (SDU) and Head of MSc Programme in Product Development and Innovation. She earned her PhD in Innovation and Technology Management from the Technical University of Denmark and holds a MSc from Copenhagen Business School. She publishes within the field of innovation management, public leadership and economic sociology in aligning societal challenges with public and private innovation efforts. Innovation systems and innovation in networks is a key feature of her expertise. She won the Christopher Pollitt Award by Sage Publishing for best published article in International Review of Public Administration in 2019.

Kirstin Kohler is professor for user experience design and design innovation at the University of Applied Sciences Mannheim. After studying Biology and Computer Science, she worked for Hewlett Packard for several years. The following 9 years Kirstin Kohler spent at Fraunhofer IESE, where she was responsible for projects related to software engineering and user experience design. In 2014, she conducted her research sabbatical in the group of Prof. Larry Leifer at Stanford (Center of Design Research / d.school). Building on this experience, she started embedding the Silicon Valley spirit of innovation in her teaching. In 2017 she established the university's innovation hub “inno.space – Design Factory Mannheim”, which is through the Design Factory Global Network and SUGAR network internationally connected with many established centers of innovation.

Thomas Rückle is the Head of Research at BioMed X Institute. In this role, he oversees all Research activities at the Institute and is the main liaison to the Pharma Partners.
Thomas studied Chemistry and Toxicology at the University of Ulm, Germany, where he received his PhD in Organic Chemistry in 1996. After two postdoctoral fellowships at the Federal Institute of Technology Lausanne (EPFL), Switzerland and at the Torrey Pines Institute for Molecular Studies, San Diego (CA), USA, he joined Serono International in Geneva (Switzerland). From 1998 to 2006 he led Research and Preclinical Programs in Autoimmune Diseases and Oncology. From 2007 onwards, Thomas held several global roles in Project Management and Translational Medicine of Neurodegenerative Diseases and Oncology. From 2012 to 2016 he was Director in Translational Medicine at Medicines for Malaria Venture, the world’s leading NGO in antimalarial R&D. Prior to BioMed X Institute, he spent 3 years as Chief Development Officer at GeNeuro. Together with his teams, Thomas has brought over a dozen molecules from Research into clinical trials.

REGISTRATION

CELIS is funded by the European Union’s COSME Programme (GA No.: 873857)